Table 5 Summary of the evaluation of reliability, ceiling effect assessment and distribution across providers of a set of indicators to measure guideline-concordant care in lung cancer patients in a pilot population of 5746 subjects

O1

First contact to first therapy ≤60 days

2386

58

2

10

12

21

69

21

68

57

80

O2

From PET to surgery ≤45 days

706

37

1

15

22

59

79

24

85

64

100

O4

From thorax CT to surgery ≤45 days

759

37

0

10

12

32

72

21

70

54

100

D1

Thorax CT at diagnosis

3086

64

5

17

26

41

78

26

81

73

100

D2

Thorax CT before biopsy

2779

76

4

22

47

62

74

27

79

57

100

D4

Cyto-histologic confirmation

3086

64

4

20

46

72

86

25

97

81

100

D5

NSCLC Stage III patients assessed for metastasis before curative intent treatment

353

37

11

5

19

51

34

34

29

0

52

S1

No death after first surgery

1124

39

1

34

37

95

96

16

100

100

100

S4

Stage I-IIIA NSCLC patients undergoing curative intent surgery

1216

47

9

11

39

83

59

38

71

18

94

S5

Stage I-IIA NSCLC patients undergoing lobectomy

1005

39

5

6

11

28

61

30

63

50

80

S6

No second surgery within 30 days

1124

39

0

33

33

85

99

4

100

100

100

S7

Hospital stay ≤14 days for first surgery

930

39

6

7

24

62

59

34

67

26

86

M1

Stage II-III NSCLC patients receiving chemo-radiation

799

92

67

4

71

77

9

22

0

0

5

M2

SCLC patients undergoing medical oncologic therapy or radiotherapy

175

56

12

18

0

0

60

38

71

29

100

M4

Pain management before death

2347

62

3

29

36

58

89

23

98

91

100

F1

Follow-up in year 2 for surviving patients

1167

45

4

8

12

27

71

27

75

65

87

Follow-up in year 3 for surviving patients

914

43

4

10

15

35

72

28

76

67

92

Follow-up in year 4 for surviving patients

711

41

4

14

19

46

77

30

89

71

100